AI
AI

Tag: Chylomicronemia

Arrowhead Pharmaceuticals Unveils New Pivotal Phase 3 Data from PALISADE Study on Plozasiran for Familial Chylomicronemia Syndrome at ESC 2024

Photo credit: www.investing.com Arrowhead Pharmaceuticals Announces Promising Phase 3 Results for Plozasiran in Familial Chylomicronemia Syndrome PASADENA, Calif.--Arrowhead Pharmaceuticals, Inc. (NASDAQ:...